EUCTR2021-003028-34-HU进行中（未招募）1 期
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C Mutation
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 136
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written ICF must be signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses.
- •-=18 years of age at the time of signing the ICF.
- •-ECOG performance status score of 0 or 1.
- •-Life expectancy =3 months.
- •-Participant must be able to provide an archived tumor sample or tumor tissue from a newly obtained biopsy from the tumor site which has not been previously irradiated.
- •-Histologically or cytologically confirmed solid tumors with KRAS G12C mutation by laboratories, which are either CLIA certified or recognized by local institution, and meets the following criteria:
- •Phase 1; Cohort A0
- •a.Have histologically or cytologically confirmed metastatic or locally advanced
- •solid tumor that is not a candidate for curative intervention.
- •b.Must have received at least 1 prior standard therapy for their tumor type and stage.
- •Phase 2; Cohort A1, A2 and Cohort B1, B2
- •a.Has histologically or cytologically confirmed diagnosis of unresectable Stage
- •IIIB or Stage IV NSCLC and is not a candidate for curative intervention.
- •b.Must have received a platinum-based therapy and an immune checkpoint
- •inhibitor unless such therapies are contraindicated or not available to the participant or the participant refused them. No more than 4 previous systemic regimens for the metastatic disease are allowed.
- •c.Participant with actionable mutations must have received appropriate targeted therapies available per local standard unless such therapies are contraindicated or not available to the participant or the participant refused them. No more than 3 previous systemic regimens for the metastatic disease are allowed.
- •d.Had received adjuvant or neoadjuvant chemotherapy and had
- •recurrence/progression on or within 6 months of completion of the therapy is
- •allowed to count the therapy as 1 previous regimen for the metastatic disease.
- •e.KRAS G12C inhibitors naïve.
- •a.KRAS G12C inhibitors naïve.
- •b.Have histologically or cytologically confirmed mCRC that is not a candidate
- •for curative intervention.
- •c.Have received no more than 4 prior systemic regimens of standard therapy for mCRC per local treatment standard deemed to be appropriate by the
- •investigator unless such therapies are contraindicated, intolerable, or the
- •participant refused them.
- •d.Systemic regimens should include a fluoropyrimidine, irinotecan, and oxaliplatin.
- •e.For mCRC participants with MSI-H disease, must have prior systemic
- •regimens with checkpoint inhibitor unless such are contraindicated or not available to the participant or the participant refused them.
- •f.Participant who had received adjuvant or neoadjuvant chemotherapy and had recurrence/progression on or within 6 months of completion of the therapy is allowed to count the therapy as 1 previous regimen for the metastatic disease.
- •For all other solid tumors:
- •g.Have histologically or cytologically confirmed metastatic or locally advanced
- •solid tumor except NSCLC that is not a candidate for curative intervention.
- •h.Must have received at least 1 prior standard therapy for their tumor type and stage.
- •a.Cohort B:
- •i.B1: KRAS G12C inhibitors naïve mCRC.
- •ii.B2: KRAS G12C inhibitors treated mCRC.
- •b.Have histologically or cytologically confirmed mCRC that is not a candidate
- •for curative intervention.
- •c.Has received no more than 4 prior systemic regimens of standard therapy for mCRC per local treatment standard deemed to be appropriate by the
- •investigator unless such therapies are contraindicate
排除标准
- •-Participant has a history of solid tumor or hematological malignancy that is histologically distinct from the cancers under study, except for cervical carcinoma in situ, superficial noninvasive bladder tumors, breast ductal carcinoma in situ, prostatic intraepithelial neoplasia without evidence of prostate cancer, or curatively treated Stage I nonmelanoma skin cancer.
- •-Participant has known serious allergy to cetuximab (Cohort B1 and B2 only) or to a G12C inhibitor (Cohort A0 and B2 only).
- •-Participant has brain or spinal metastases except if treated by surgery, surgery plus radiotherapy or radiotherapy alone, with no evidence of radiographic progression or hemorrhage for at least 28 days before the start of treatment with the study drugs, and if applicable, on stable dose of systemic corticosteroids for at least 28 days before the start of treatment with the study drugs.
- •-Active infection requiring systemic treatment at the start of treatment in this trial.
- •-Participants testing positive for HIV are NOT excluded from this study, but HIV positive participants must meet certain criteria.
- •-Has active HBV or HCV.
- •Note:Participants with HBV who have controlled infection (serum HBV DNA PCR that is below the limit of detection) are permitted. Participants with controlled infections must undergo periodic monitoring of HBV DNA.
- •Note:Participants who are HCV antibody positive who have controlled infection may be enrolled into the study. Participants with controlled infections must undergo periodic monitoring of HCV RNA by their treating physician.
- •-History (=6 months before the start of treatment) of any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator and sponsor, could affect the participant’s participation in the study.
- •-History (=6 months before the start of treatment with the study drugs) of any of the following: acute myocardial infarction, unstable angina pectoris, coronary artery bypass graft, or cerebrovascular accident.
- •-Participants who have impaired cardiac function or clinically significant cardiac
- •-Participants with QT interval >470 msec at Screening using QTcF, determined as the mean of 3 QTcF values from the screening triplicate ECG.
- •-Participants experiencing unresolved Grade >1 toxicity before the start of treatment with the study drug except for hair loss (alopecia) and stable Grade 2 toxicities (stable defined as more than 3 months, if permitted by the investigator and medical monitor).
- •-Women who are pregnant or breast-feeding.
- •-Has received or will receive a live vaccine within 30 days prior to the first
- •administration of study medication. Seasonal flu vaccines that do not contain live vaccine are permitted.
- •-Has known psychiatric or substance abuse disorders that would interfere with
- •cooperation with the requirements of the trial.
- •-History of an allogeneic bone marrow or solid organ transplant.
- •-Use of systemic anticancer agent or investigational drug is prohibited =28 days for biologics and IV chemotherapy, or =21 days or 5 half-lives (whichever is longer) for small molecules prior to the first dose of JAB-21822.
- •-History of radiation therapy =14 days prior to the first dose of study drug.
- •-Prophylactic administration of G-CSF, filgrastim, pegfilgrastim, blood transfusion, platelet packets, and erythropoietin are not allowed during =4 weeks before the start of treatment and during Cycle 1 of the Dose Escalation Phase.
- •-Use of drugs known to be moderate
研究者
相似试验
已完成
2 期
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C Mutation2024-515258-25-00Jacobio Pharmaceuticals Co. Ltd.111
进行中（未招募）
1 期
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients with Advanced Solid Tumors Harboring KRAS G12C MutatioCTIS2024-515258-25-00Jacobio Pharmaceuticals Co. Ltd.136
招募中
1 期
First-in-human, Phase 1/2, open-label, multicenter, dose-escalation and expansion studyCTIS2022-502645-99-00Tango Therapeutics Inc.173
进行中（未招募）
1 期
A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with Worsening (relapsed) or Unresponsive (refractory) Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)Diffuse Large B-Cell Lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003855-40-CZMorphoSys AG51
进行中（未招募）
1 期
A Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with Worsening (relapsed) or Unresponsive (refractory) Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)Diffuse Large B-Cell Lymphoma (DLBCL)MedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003855-40-ATMorphoSys AG51